Home›Stock Screener›Gufic BioSciences›Quarterly Results

Gufic BioSciences Quarterly Results

Latest Quarter Net Profit
₹22 Cr
QMar 2026
Quarterly Results

Gufic BioSciences quarterly results. In Mar 2026, Gufic BioSciences (GUFICBIO) reported revenue ₹251 Cr and net profit ₹22 Cr — revenue +22.4% YoY. Review GUFICBIO price earnings ratio to evaluate earnings-based valuation against sector peers.

GUFICBIO Quarterly Results — Revenue, Profit & EPS Highlights

Gufic BioSciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Gufic BioSciences screener.

  • Revenue of ₹251 Cr in Mar 2026 (-3.8% vs Jun 2026, +22.4% vs Mar 2025)
  • Net Profit of ₹22 Cr in Mar 2026 (+0.0% vs Jun 2026, +175.0% vs Mar 2025)
  • EBITDA of ₹46 Cr in Mar 2026 (-2.1% vs Jun 2026)
  • Operating Margin of 19.0% in Mar 2026 (+1.0pp vs Jun 2026)
  • Earnings Per Share of ₹2.18 in Mar 2026 (-1.8% vs Jun 2026)

Gufic BioSciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS

GUFICBIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 251 261 239 205 225 -3.8% 22.4%
Net Profit (₹ Cr) 22 22 17 8 13 - -
EBITDA (₹ Cr) 46 47 40 27 34 - -
EPS (₹) 2.18 2.22 1.68 0.77 1.30 - -
Operating Margin (%) 19.0% 18.0% 16.0% 13.0% 15.0% - -

GUFICBIO Share Price Trend — 1-Year Movement Across Quarterly Results

Gufic BioSciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check Gufic BioSciences networth to track the company's total market size over time.

Profitability Ratios

Profit Margin 8.8%
EBITDA Margin 18.3%
Operating Margin 19.0%
ROE (Annual) 13.2%

Balance Sheet Highlights

Total Assets ₹1,342 Cr
Total Equity ₹665 Cr
Current Assets ₹802 Cr
Current Liabilities ₹160 Cr

Cash Flow Analysis

Operating Cash Flow ₹45 Cr
Investing Cash Flow ₹-31 Cr
Financing Cash Flow ₹32 Cr
Net Cash Flow ₹47 Cr

Current Market Data

Current Price ₹419.70
Exchange NSE
Last Updated Oct 05, 2026

Revenue Trend (₹ Cr)

Mar 2025 205
Sept 2025 239
Jun 2026 261
Mar 2026 251

Net Profit Trend (₹ Cr)

Mar 2025 8
Sept 2025 17
Jun 2026 22
Mar 2026 22

Operating Margin Trend (%)

Mar 2025 13.0%
Sept 2025 16.0%
Jun 2026 18.0%
Mar 2026 19.0%

GUFICBIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Gufic BioSciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹432,120.23 Cr 1779.7 15,018 2,710 -5.6% - 18.0% 157.5
Divis Laboratories
Mar 2026 		₹253,522.49 Cr 9196.0 2,986 751 -5.0% - 25.2% 324.8
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4772.0 4,111 364 +27.7% +42.2% 8.9% 414.6
Zydus Life Science
Mar 2026 		₹113,615.69 Cr 1139.0 7,569 1,341 -4.3% - 17.7% 90.0
Cipla
Mar 2026 		₹108,576.18 Cr 1335.5 6,612 543 -9.3% - 8.2% 194.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores